AZD-1613

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameAZD-1613
Drug Alias NameAZD1613AZD-1613
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPolycystic Kidney, Autosomal DominantPolycystic Kidney Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAstrazeneca Ab
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstraZeneca global R & D (China) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPolycystic Kidney, Autosomal DominantPolycystic Kidney Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A